Navigation Links
Cholesterol necessary for brain development
Date:10/2/2009

[PRESS RELEASE, 2 October 2009] A derivative of cholesterol is necessary for the formation of brain cells, according to a study from the Swedish medical university Karolinska Institutet. The results, which are published in the journal Cell Stem Cell, can help scientists to cultivate dopamine-producing cells outside the body.

The study was led by Professor Ernest Arenas and demonstrates that the formation of dopamine-producing neurons during brain development in mice is dependent on the activation of a specific receptor in the brain by an oxidised form of cholesterol called oxysterol. Dopamine-producing nerve cells play an important part in many brain functions and processes, from motor skills to reward systems and dependency. They are also the type of cell that dies in Parkinson's disease.

The scientists have also shown that embryonic stem cells cultivated in the laboratory, form more dopamine-producing nerve cells if they are treated with oxidised cholesterol. The same treatment also reduced the tendency of the stem cells to show uncontrolled growth.

"Oxysterol contributes to a safer and better cultivation of dopamine-producing cells, which is a great advancement since it increases the possibility of developing new treatments for Parkinson's disease," says Professor Arenas.

It is hoped that one day it will be possible to replace dead cells in the brains of Parkinson's patients with transplanted cultivated dopamine-producing cells. Such cells can also be used to test new Parkinson's drugs.


'/>"/>

Contact: Press Officer Katarina Sternudd
katarina.sternudd@ki.se
46-852-483-895
Karolinska Institutet
Source:Eurekalert

Page: 1

Related biology news :

1. Cholesterol-busting bug with a taste for waste
2. Lowering your cholesterol may decrease your risk of cancer
3. Hypertension and cholesterol medications present in water released into the St. Lawrence River
4. New genes present drug targets for managing cholesterol and glucose levels
5. Researchers learn that some good cholesterol isnt good enough
6. A scientific breakthrough on the control of the bad cholesterol
7. MSU researcher studies ties between cholesterol drugs, muscle problems
8. Penn biophysicists create new model for protein-cholesterol interactions in brain and muscle tissue
9. Cholesterol-lowering drugs and the effect on muscle repair and regeneration
10. Mitochondrial cholesterol makes response to chemotherapy difficult in hepatic cancer
11. Niacins role in maintaining good cholesterol
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2016)... , Dec 15, 2016 ... Research and Markets has announced the ... their offering. The report forecasts the global military biometrics ... The report has been prepared based on an in-depth ... landscape and its growth prospects over the coming years. The report also ...
(Date:12/15/2016)... LONDON , Dec. 14, 2016 "Increase ... mobile biometrics market" The mobile biometrics market is expected ... USD 49.33 billion by 2022, at a CAGR of ... by factors such as the growing demand for smart ... mobile transactions. "Software component is expected to ...
(Date:12/8/2016)... , Dec. 8, 2016  Singulex, Inc., the leader ... technology, entered into a license and supply agreement with ... The agreement provides Singulex access to Thermo Scientific BRAHMS ... is used to diagnose systemic bacterial infection ... to aid in assessing the risk of ...
Breaking Biology News(10 mins):
(Date:1/24/2017)... - BioAmber Inc. (NYSE: BIOA ) today announced ... Rodman & Renshaw, a unit of H.C. Wainwright ... representative of several underwriters, under which the underwriters have ... minimum of 2,105,264 shares of common stock of the ... 1,052,632 shares of common stock of the Company with ...
(Date:1/23/2017)... , Jan. 23, 2017  Spherix Incorporated (Nasdaq: ... committed to the fostering of technology and monetization of ... patent infringement lawsuits. Anthony Hayes , ... 2017, we will continue to communicate with shareholders about ... and our due diligence on other patent assets that ...
(Date:1/23/2017)... Resverlogix Corp. ("Resverlogix" or the "Company") (TSX: RVX) today ... based Phase 1 trial with severe kidney ... reducing inflamed protein biomarkers in patients with severe kidney ... this is the first time in medical history that ... between epigenetic regulation and its potential for positive disease ...
(Date:1/23/2017)... ... January 23, 2017 , ... Calvert Labs, Inc. announced ... and Senior Director, Safety Pharmacology. Dr. Thomas earned his M.Sc. and Ph.D. ... career as an academic and industry preclinical drug developer spans more than three ...
Breaking Biology Technology: